Translate article text
Choose a language and wait for the translated text.
Repligen’s $1.5bn purchase of BioLife Solutions adds CryoStor biopreservation to its bioprocessing portfolio, underscoring pharma’s shift toward integrated cell and gene therapy supply chains.
